Drug Development

NKGen Biotech is pioneering an immune therapy for neurodegeneration. But its true innovation may be a strategic pivot to Asia's fast-track regulatory pathways.

Starton Therapeutics heads to a key investor conference not with a new molecule, but a new method. Can their delivery tech turn old drugs into new blockbusters?

Third Arc Bio's move to fund clinical development for a new cancer drug validates Adagene's SAFEbody platform, de-risking its finances and setting the stage.

A €30M investment from the EIB and HERA is backing Ethris's novel mRNA therapeutic. Delivered via nasal spray, it aims to treat chronic respiratory ills and act as a broad-spectrum antiviral.

With a key investor conference ahead, MacroGenics balances promising cancer drug data against a history of clinical setbacks and a major strategic pivot.

Dr. Timothy Donahue's new leadership at Weill Cornell while on Trethera's board highlights a key trend: integrating top clinical minds to accelerate drug development.

PhenoNet completes a key trial milestone for its ALS therapy, not with a new molecule, but with a repurposed drug and a savvy regulatory and operational plan.

As Aktis Oncology presents at key investor conferences, it showcases a precision miniprotein platform and a major Eli Lilly deal in a booming market.

With Phase 3 data imminent and a new Nasdaq ticker, Helus Pharma is using a key investor conference to frame its novel therapies as the next frontier.

As Cardiol Therapeutics prepares for a key investor conference, it's not just a presentation; it's a test of its strategy to build a durable franchise in heart disease.

A veteran team with a pharma exit under its belt just raised $10.8M to aim AI at a notoriously tough drug target. Here’s why investors are buying the signal.

Cure Alzheimer's Fund is recruiting top drug developers, including the mind behind Kisunla™, to steer its research—all while refusing industry money.

An analysis of Chiesi’s H1 results reveals a strategy where strategic acquisitions and deep R&D investment drive both profit and a €6B economic footprint.

With a massive cash infusion and novel brain-delivery tech, newly public Korsana Biosciences is betting it can succeed where many have failed in neurodegeneration.

With a key conference appearance, OPKO Health aims to translate its deep R&D pipeline into market confidence. Will investors buy into its long-term vision?

With new patents in Australia and Japan, Leveragen isn't just protecting its tech. It's building a data-rich biological engine for AI-driven medicine.

The Vancouver biotech is advancing a dual-targeting CAR and a safer STING therapy, betting that precision and strategy will pave its path to NASDAQ and beyond.

With a $70M boost and backing from Eli Lilly, Moonwalk Biosciences aims to redefine obesity treatment by targeting fat tissue directly, not appetite.

New AI-powered analysis of Endeavor BioMedicines' taladegib shows significant lung volume gains, offering a glimmer of hope for reversing damage in IPF.

As BioVie seeks FDA approval for a pivotal Phase 3 trial, its novel anti-inflammatory drug could usher in a new era for Parkinson's patients.